PMID- 1964664
OWN - NLM
STAT- MEDLINE
DCOM- 19910516
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 20 Suppl 1
DP  - 1990
TI  - Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight 
      heparin (CY216).
PG  - 220-3
AB  - Ninety consecutive outpatients with acute proximal and/or distal deep-vein 
      thrombosis (DVT), as shown by phlebography, were entered into a prospective 
      randomized trial comparing intravenous adjusted unfractionated heparin (UFH) with 
      subcutaneous fixed doses of a low-molecular-weight heparin (CY216; 225 IC anti-Xa 
      U/kg 12 hourly) for 10 days. The incidence of pulmonary embolism did not differ 
      in the two groups (one episode per group). The comparison between pre- and 
      posttreatment venograms and perfusion lung scans showed a statistically 
      significant improvement (p less than 0.01 and p less than 0.05, respectively) 
      only in the CY216-treated group. The incidence of major adverse reactions (major 
      hemorrhages, relevant hemoglobin fall, and serious thrombocytopenia) was 
      significantly higher (22 vs. 4.5%; p = 0.01) in the UFH-treated group. After a 
      mean follow-up period of 2 years, the incidence of thromboembolic recurrences and 
      that of post-thrombotic manifestations did not differ in the two groups. It is 
      concluded that subcutaneous fixed doses of CY216 are more effective and safer 
      than intravenous adjusted UFH in the treatment of acute DVT.
FAU - Prandoni, P
AU  - Prandoni P
AD  - 2nd Department of Internal Medicine, University of Padua, Italy.
FAU - Vigo, M
AU  - Vigo M
FAU - Cattelan, A M
AU  - Cattelan AM
FAU - Ruol, A
AU  - Ruol A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Drug Administration Schedule
MH  - Heparin, Low-Molecular-Weight/*administration & dosage/adverse effects
MH  - Humans
MH  - Prospective Studies
MH  - Recurrence
MH  - Thromboembolism/prevention & control
MH  - Thrombophlebitis/complications/*drug therapy
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
AID - 10.1159/000216180 [doi]
PST - ppublish
SO  - Haemostasis. 1990;20 Suppl 1:220-3. doi: 10.1159/000216180.